James Shipp, MD
Ophthalmology · Oxford, MSNPI 1427212992
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,325 of the $20,615 with a category attached, or 79.2%. Rxsight Inc accounts for 81.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $16,951 and has fallen 90.4% since, to $1,634 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $129.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$17K
- Alcon$1K
- Mallinckrodt Hospital Products Inc.$864
- Amgen$298
- AbbVie$293
- Ocular Therapeutix, Inc.$188
- plus $756 from 23 others
Across 3 payments — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$12K
What the payments were for
- Consulting fees$16,32579%
- Speaking & faculty fees$260%
- Travel & lodging$9315%
- Food & beverage$3,28916%
- Gifts$190%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 13 | $16,851 |
| Alcon | 26 | $1,365 |
| Mallinckrodt Hospital Products Inc. | 46 | $864 |
| Amgen(2 entities) | 16 | $298 |
| AbbVie(2 entities) | 9 | $293 |
| Ocular Therapeutix, Inc. | 10 | $188 |
| Ivantis, Inc | 2 | $76 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $72 |
| Biotissue Holdings Inc. | 5 | $70 |
| Sight Sciences, Inc. | 3 | $51 |
| Oyster Point Pharma, Inc. | 2 | $50 |
| Bausch & Lomb Americas Inc. | 3 | $50 |
| Johnson & Johnson Vision Care, Inc. | 2 | $39 |
| Coopervision Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $32 |
| Glaukos Corporation | 1 | $28 |
| Sun Pharmaceutical Industries Inc. | 1 | $26 |
| Dompe US, Inc. | 1 | $26 |
| Nova Eye, Inc. | 1 | $26 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Carl Zeiss Meditec USA, Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| NEW World Medical,inc. | 1 | $17 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| Mindray DS USA, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Beaver-visitec International, Inc. | 1 | $12 |
| Eyepoint US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,615 in reported general payments places this provider in the 95th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 11 | $672,952 |
| RestasisCyclosporine | 12 | $14,820 |
| LumiganBimatoprost | 29 | $10,678 |
| TyrvayaVarenicline Tartrate | 15 | $7,704 |
| Prednisolone Acetate | 73 | $2,475 |
| Brimonidine Tartrate | 28 | $2,132 |
| Travoprost | 21 | $1,905 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 67 | $1,598 |
| Latanoprost | 146 | $1,157 |
| Fluorometholone | 19 | $1,098 |
| Timolol Maleate | 51 | $410 |
| ErythromycinErythromycin Base | 16 | $184 |
| Dorzolamide Hcl | 13 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $864 | $672,95211 claims |
| AbbVieRestasis, Lumigan | $293 | $25,49941 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $50 | $7,70415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Oxford
- Jonathan ZoghbyOxford$6K
- Thomas TannOxford$4K
- William FarmerOxford$4K
- Blake BoothOxford$4K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.